Prosecution Insights
Last updated: November 04, 2026
Application No. 16/636,606

BENZIMIDAZOLES AND AZA-BENZIMIDAZOLES, AND METHODS OF USE THEREOF

Final Rejection §102
Filed
Feb 04, 2020
Priority
Aug 04, 2017 — provisional 62/541,457 +2 more
Examiner
HASTINGS, ALISON AZAR
Art Unit
1627
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Goldfinch Bio Inc.
OA Round
12 (Final)
63%
Grant Probability
Moderate
13-14
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allowance Rate
57 granted / 91 resolved
+2.6% vs TC avg
Strong +40% interview lift
Without
With
+40.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
52 currently pending
Career history
141
Total Applications
across all art units

Statute-Specific Performance

§101
2.7%
-37.3% vs TC avg
§103
31.2%
-8.8% vs TC avg
§102
19.4%
-20.6% vs TC avg
§112
27.1%
-12.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 91 resolved cases

Office Action

§102
DETAILED ACTION All objections or rejections not mentioned below have been withdrawn. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 102 -New Due to Amendments In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 77 and 94 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by TRENT (TRENT et al., WO-2011127333-A2, 13 October 2011). The reference TRENT teaches the following compound(page 8): PNG media_image1.png 381 817 media_image1.png Greyscale This is the same compound as the third compound from last of instant claim 77. This anticipates claim 77. The reference TRENT teaches the following “In some embodiments, the pharmaceutical composition can include one or more formulary ingredients. A "formulary ingredient" can be any suitable ingredient (e.g., suitable for the drug(s), for the dosage of the drug(s), for the timing of release of the drugs(s), for the 20 disease, for the disease state, or for the delivery route) including, but not limited to, water (e.g., boiled water, distilled water, filtered water, pyrogen-free water, or water with chloroform), sugar (e.g., sucrose, glucose, mannitol, sorbitol, xylitol, or syrups made therefrom), ethanol, glycerol, glycols (e.g., propylene glycol), acetone, ethers, DMSO, surfactants (e.g., anionic surfactants, cationic surfactants, zwitterionic surfactants, ornonionic 25 surfactants (e.g., polysorbates)), oils (e.g., animal oils, plant oils (e.g., coconut oil or arachis oil), or mineral oils), oil derivatives (e.g., ethyl oleate , glyceryl monostearate, or hydrogenated glycerides), excipients…”[00121] and “A composition comprising a compound of Formula (I), wherein the composition is a pharmaceutical composition”(reference claim 37). The reference also teaches “The composition of claim 37, wherein the compound of Formula (I) is selected from the 30 group consisting of I-I to I-46”(reference claim 42). This anticipates claim 94. Response to Arguments Applicant’s arguments (09/15/2026) with respect to the claim(s), have been considered but are moot because the new ground of rejection does not rely on any reference applied in the prior rejection of record for any teaching or matter specifically challenged in the argument. Conclusion Claims 77 and 94 are rejected. Claims 95-98, 101, 103 are withdrawn. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ALISON AZAR HASTINGS whose telephone number is (703)756-4584. The examiner can normally be reached Mon-Thurs 7:30am-5pm EST Friday 7:30-4pm EST (every other Friday off). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kortney Klinkel can be reached at (571) 270-5239. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /A.A.H./ Examiner, Art Unit 1627 /Kortney L. Klinkel/ Supervisory Patent Examiner, Art Unit 1627
Read full office action

Prosecution Timeline

Show 24 earlier events
Oct 10, 2025
Non-Final Rejection mailed — §102
Jan 12, 2026
Response Filed
Feb 26, 2026
Final Rejection mailed — §102
May 26, 2026
Request for Continued Examination
May 27, 2026
Response after Non-Final Action
Jun 16, 2026
Non-Final Rejection mailed — §102
Sep 15, 2026
Response Filed
Oct 09, 2026
Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778914
USE OF COMPOSITION OF ALCOHOL AND COOLING AGENT IN REGULATING SEXUAL FUNCTIONS, PROTECTING CARDIOVASCULAR AND CEREBROVASCULAR SYSTEMS, PROMOTING REGENERATION OF LIVER CELLS, PREVENTING AND/OR TREATING TUMORS, AND IMPROVING IMMUNITY AND SLEEP QUALITY
2y 11m to grant Granted Nov 03, 2026
Patent 12774281
HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING
4y 2m to grant Granted Oct 27, 2026
Patent 12766127
ANTI-VIRAL COMPOUNDS AND METHODS FOR SCREENING SAME AND TREATING VIRAL INFECTIONS
3y 9m to grant Granted Oct 20, 2026
Patent 12759987
CARDIAC THERAPEUTIC
4y 9m to grant Granted Oct 13, 2026
Patent 12760001
COMPOSITIONS AND METHODS FOR SYSTEMIC DELIVERY OF Bcl-2 AND Bcl-xL ANTAGONISTS
4y 4m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

13-14
Expected OA Rounds
63%
Grant Probability
99%
With Interview (+40.3%)
3y 3m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 91 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month